Bacterial filtration efficiency (BFE) testing is the core performance evaluation used to verify how effectively a medical mask captures airborne bacteria, and it is a mandatory requirement under standards such as ASTM F2101, ASTM F2100, EN 14683, YY 0469, and GB 19083. This technical article explains the BFE test principle, apparatus, procedure, calculation, acceptance criteria, and typical applications for regulatory registration and quality control of medical face masks.
Technical Overview
Bacterial filtration efficiency (BFE) quantifies the ability of a medical face mask material to block aerosolized bacterial particles, expressed as the percentage of a controlled bacterial aerosol challenge that is retained by the mask. BFE is one of the most critical safety and performance indicators for medical masks because it directly reflects the product's capacity to reduce the transmission of microorganisms between the wearer and the patient during clinical procedures.
BFE testing is performed on a biological aerosol of Staphylococcus aureus using a cascade impactor sampling system operated at a fixed airflow of 28.3 L/min. The test methods are defined in recognized standards published by standards organizations, primarily ASTM F2101 and EN 14683 (Annex B), with product performance classes specified in ASTM F2100, EN 14683, YY 0469, YY/T 0969, and GB 19083.
The principal acceptance criteria for BFE in the major standards are summarized below:
- ASTM F2100 Level 1: BFE ≥ 95%
- ASTM F2100 Level 2 and Level 3: BFE ≥ 98%
- EN 14683 Type I: BFE ≥ 95%
- EN 14683 Type II and Type IIR: BFE ≥ 98%
- YY 0469 (surgical mask, China): BFE ≥ 95%
- GB 19083 (medical protective mask, China): BFE ≥ 95%
Because BFE results are used for regulatory registration, batch release, and market access in China, the European Union, North America, and other regions, testing is typically carried out by accredited third-party laboratories operating under biosafety level 2 (BSL-2) conditions with validated BFE test systems.
Testing Samples
Medical Face Masks and Surgical Masks
The most common test articles are single-use medical face masks and surgical masks constructed from layered nonwoven materials such as spunbond polypropylene and meltblown filtration media. Specimens are cut from the mask body so that all layers of the finished product, including any reinforcing or shaping layers, are challenged together as an integral structure.
Medical Protective Masks
Medical protective masks intended for use in high-risk healthcare environments are evaluated against GB 19083 or equivalent protective mask standards. These products must demonstrate a high BFE in addition to submicron particulate filtration efficiency, splash resistance, and breathing resistance.
Filtration Materials and Components
Raw filtration media, meltblown nonwoven fabrics, and composite laminate materials can also be submitted for BFE evaluation during material development, supplier qualification, or incoming inspection. Testing materials at an early stage helps manufacturers verify filtration performance before finished product assembly.
Specimen Preparation and Conditioning
A minimum of five specimens is generally required for each sample. Prior to testing, specimens are conditioned at a temperature of 21 ± 5 °C and a relative humidity of 85 ± 5% for at least 4 hours to standardize the moisture content of the nonwoven materials, which can influence electrostatic and mechanical capture of bacterial particles.
Testing Items
BFE is the primary test item, but it is usually assessed as part of a complete performance profile required by the applicable product standard. Typical associated test items include:
- Bacterial filtration efficiency (BFE) per ASTM F2101 or EN 14683
- Differential pressure (breathing resistance, ΔP) to confirm breathability alongside filtration performance
- Particulate filtration efficiency (PFE) for submicron particles, typically per ASTM F2299
- Resistance to penetration by synthetic blood for surgical masks subject to fluid splash exposure
- Microbial cleanliness (bioburden) of the mask material
- Flammability classification, where required by the target market
When reviewing test reports, evaluators should confirm that the report states the applied standard, the challenge organism, the mean particle size, the airflow rate, the conditioning conditions, the individual specimen results, and the mean BFE value.
Testing Methods
Test Principle
A liquid suspension of Staphylococcus aureus (ATCC 6538) is aerosolized with a nebulizer inside an enclosed aerosol chamber. The bacterial aerosol is drawn at a constant flow rate of 28.3 L/min through a mask specimen mounted in a sample holder and then into a six-stage Andersen cascade impactor, which collects viable particles on agar plates according to aerodynamic particle size. The number of colonies penetrating the mask is compared with the number collected in control runs performed without a specimen, and the BFE is calculated from the difference.
Challenge Aerosol Characteristics
The aerosol must be maintained within strictly validated parameters to ensure comparability between laboratories:
- Challenge organism: Staphylococcus aureus, subsp. aureus, ATCC 6538
- Mean particle size: 3.0 ± 0.3 μm
- Total challenge level per run: approximately 1,700 to 3,000 colony forming units (CFU)
- Airflow rate through the test system: 28.3 L/min
Apparatus
The test system consists of an aerosol generator (nebulizer), an aerosol chamber with specimen holder, a six-stage Andersen cascade impactor with agar collection plates, a vacuum pump or air sampling pump, and an incubator. An aerodynamic particle sizer or equivalent instrument is used to verify the aerosol particle size distribution during method validation.
Test Procedure
- Condition the specimens at 21 ± 5 °C and 85 ± 5% relative humidity for a minimum of 4 hours.
- Prepare the bacterial challenge suspension and load the nebulizer.
- Run a positive control (no specimen) to determine the total aerosol challenge delivered to the sampler.
- Mount a mask specimen in the holder with the challenge side facing the aerosol source, as specified by the standard.
- Draw the aerosol through the specimen and the cascade impactor at 28.3 L/min for the prescribed sampling period.
- Transfer the agar plates from all six impactor stages to an incubator set at 35 ± 2 °C for approximately 48 hours.
- Count the colonies on each stage, applying stage correction if necessary, and record the total count for the run.
- Repeat the procedure for the remaining specimens and for negative control runs to confirm system sterility.
Calculation of BFE
The bacterial filtration efficiency of each specimen is calculated using the total colony counts from the specimen run and the mean total count from the positive control runs:
BFE (%) = [(C − T) / C] × 100, where C is the mean total CFU recovered from the positive control runs and T is the total CFU recovered from all impactor stages during the specimen run. The final reported result is typically expressed as the mean BFE of all tested specimens, and each individual result must meet or exceed the acceptance criterion for the product to conform.
Quality Control and Biosafety
Testing must be performed in a BSL-2 microbiology laboratory by trained personnel using validated equipment, calibrated flow meters, and documented positive and negative controls. Regular verification of aerosol particle size, challenge concentration, and impactor stage performance is essential to ensure the accuracy and reproducibility of BFE results.
Applications
BFE test data serve a wide range of regulatory, commercial, and technical purposes across the medical mask supply chain:
- Regulatory registration and market access: BFE reports from accredited third-party laboratories support medical device registration submissions and product listings in major markets, including China, the European Union, and North America.
- Standard conformity demonstration: Manufacturers use BFE data to classify products into the correct performance levels, such as ASTM F2100 Level 1–3 or EN 14683 Type I, II, and IIR.
- Batch release and routine quality control: Periodic BFE verification confirms that production lots maintain the filtration performance established during type testing.
- Material development and supplier qualification: Nonwoven fabric producers and mask manufacturers evaluate meltblown media and electret-treated materials to optimize filtration efficiency while maintaining acceptable breathing resistance.
- Procurement and tender verification: Hospitals, government agencies, and distributors rely on independent BFE test reports to verify supplier claims before purchase.
- Export compliance: BFE documentation is frequently requested during customs clearance and conformity assessment for exported medical masks.
FAQ
What is bacterial filtration efficiency (BFE)?
BFE is the percentage of a standardized bacterial aerosol, generated from Staphylococcus aureus with a mean particle size of about 3 μm, that is captured by a medical face mask material under controlled laboratory airflow conditions. A BFE of 95% means the mask retained 95% of the viable bacterial particles in the challenge aerosol.
Which standards govern BFE testing for medical masks?
The principal test method standards are ASTM F2101 and EN 14683. Product performance requirements are specified in ASTM F2100, EN 14683, YY 0469, YY/T 0969, and GB 19083, each defining the minimum BFE and associated performance criteria for the corresponding mask categories.
Why is Staphylococcus aureus used as the challenge organism?
Staphylococcus aureus (ATCC 6538) is used because it is a clinically relevant opportunistic pathogen that survives aerosolization well, forms countable colonies on standard agar, and can be generated with a stable particle size distribution around 3 μm, which is representative of bacteria-laden respiratory droplets.
How is BFE different from particulate filtration efficiency (PFE)?
BFE measures the capture of viable bacteria carried in relatively large liquid droplets around 3 μm, whereas PFE evaluates filtration of submicron inert particles, typically around 0.1 μm latex spheres per ASTM F2299. The two tests assess different capture mechanisms and are complementary parts of a complete mask performance assessment.
How many specimens are required for a BFE test?
A minimum of five specimens per sample is generally specified, with the mean BFE reported alongside individual results. Laboratories may test additional specimens if results are borderline or if the standard requires confirmation.
Does a high BFE guarantee that a mask protects the wearer?
No. BFE evaluates the filtration capability of the mask material itself, not the fit or leakage around the edges of the mask. Real-world protection also depends on design, facial seal, breathing resistance, and correct donning procedures, which is why BFE is always considered together with differential pressure and other performance parameters.
Do respirators such as N95-type products require BFE testing?
Respirators evaluated under respiratory protection standards are primarily assessed by particulate filtration efficiency and total inward leakage. However, when a respirator is also marketed as a medical face mask for clinical use, BFE testing is typically required in addition to the respirator performance testing.
How should manufacturers prepare for BFE testing?
Manufacturers should confirm the applicable standard for the target market, submit representative samples from normal production, ensure the laboratory is accredited and uses a validated BFE apparatus, and review the report to verify that the challenge level, particle size, flow rate, and conditioning conditions are all documented in accordance with the standard.
